Cardiff Oncology (NASDAQ:CRDF) vs. Finch Therapeutics Group (NASDAQ:FNCH) Head to Head Survey

Finch Therapeutics Group (NASDAQ:FNCH) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Finch Therapeutics Group and Cardiff Oncology, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Finch Therapeutics Group	0	0	0	0	N/A
Cardiff Oncology	0	0	2	0	3.00

Cardiff Oncology has a consensus price target of $10.50, indicating a potential upside of 217.22%. Given Cardiff Oncology’s higher possible upside, analysts plainly believe Cardiff Oncology is more favorable than Finch Therapeutics Group.

Profitability

This table compares Finch Therapeutics Group and Cardiff Oncology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Finch Therapeutics Group	N/A	-136.63%	-57.40%
Cardiff Oncology	-6,594.92%	-54.54%	-47.11%

Valuation and Earnings

This table compares Finch Therapeutics Group and Cardiff Oncology’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Finch Therapeutics Group	$110,000.00	31.91	-$74.75 million	($47.67)	-0.05
Cardiff Oncology	$490,000.00	302.09	-$41.44 million	($0.90)	-3.68

Cardiff Oncology has higher revenue and earnings than Finch Therapeutics Group. Cardiff Oncology is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

21.8% of Finch Therapeutics Group shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 44.9% of Finch Therapeutics Group shares are held by insiders. Comparatively, 6.3% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Finch Therapeutics Group has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500.

Summary

Cardiff Oncology beats Finch Therapeutics Group on 9 of the 13 factors compared between the two stocks.

About Finch Therapeutics Group

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.